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INTRODUCTION 
Tuberculosis is the first cause of death among people living with HIV1 and perpetuates poverty and 
inequalities in low-income countries2-4. In 2010, 8.8 million of new cases of TB were reported 
worldwide, of which 350,000 among HIV positive population5. In Kenya, in 2008-2009, the 
HIV/AIDS prevalence rate was 6.3%6. This national average masks huge disparities, and the 
prevalence rate was 13.9% in the Homa Bay district, where MSF intervenes since 1996. At Homa Bay, 
70% of TB cases are HIV infected7.  
Smear microscopy has a low sensitivity (50%) compared to the Mycobacterium tuberculosis (MTB) 
culture reference standard8. This sensitivity is even more reduced in HIV infected patient9-11. In 2007, 
the WHO reviewed its diagnostic algorithms for smear-negative patients and recommended, when 
available, MTB culture and an earlier and systematic chest X-ray examination12. However, culture 
requires high infrastructure level, highly qualified staff and scrupulous respect of safety standards12. 
Due to the very low access to the MTB cultures in resource-limited settings, smear-negative TB 
suspected patient are diagnosed on the basis of clinical examination, chest X-ray and absence of 
response to an antibiotic trial targeting bacterial pneumonias13. The performances of these diagnostic 
algorithms are disappointing, leading to a sub-diagnosis of true TB cases and overtreatment of non-TB 
cases14.  
The MGIT liquid culture method is the most sensitive culture but remains expensive and has an 
increased safety risk compared to methods using solid media14. There are non-commercial alternatives, 
such as Thin Layer Agar culture (TLA)15, based on the microscopic observation of MTB on agar 
medium. Sensitivity is close to the Löwenstein-Jensen (LJ) classical method, but faster (10-15days 
against 30-40 days for LJ)16-19. To improve the TB diagnosis in the Homa Bay District, MSF 
introduced the TLA and LJ cultures in the laboratory of the district hospital20. 
This study aims to address the question whether the introduction of the rapid non-commercial TLA 
culture together with LJ culture increased the number of true TB patients started on treatment among 
smear-negative pulmonary TB suspects and for which cost.  
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METHODS  
Diagnostic algorithms  
The conventional diagnostic algorithm based on clinical, radiological features and use of an antibiotic 
trial is compared with the culture-based algorithm which includes the TLA and LJ cultures in addition 
to the conventional algorithm (Figures 1 and 2). The diagnostic algorithm included several steps after 
which some patients could be started on TB treatment.  
In the conventional algorithm, when the chest X-ray and/or clinical examination were suggestive of 
TB, patients were started on TB treatment (A block). Otherwise, they received an antibiotic trial 
(amoxicilline 1g 3x/j) for five days followed by a second clinical examination and sputum microscopy 
examination. The decision to start or not a TB treatment was decided by the clinician (B block) who 
could prescribe a second antibiotic treatment and perform a third clinical examination (C block).  
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Figure 1: Conventional diagnostic algorithm without culture 
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In the culture-based algorithm, culture was introduced from the A block for every patients. If the 
culture was positive and the patient was not already treated for TB the patient was contacted and 
traced to start the TB treatment. The rest of the management process was the same as in the 
conventional algorithm. 
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Figure 2: TLA/LJ culture results  
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The protocol was approved by the Kenya Medical Research Institute Ethical Review Committee and 
by the Ethical Review Committee at the ‘‘Comite´de Protection des Personnes’’, Saint Germain en 
Laye, in France. Written informed consent was obtained from all study participants as well as from 
guardians on the behalf of the minor participants before enrolment in the study. The written informed 
consent was approved by the Ethics Committees. 
 
Study population  
The effectiveness criterion, expressed in terms of true TB cases (positive culture) started on treatment, 
were obtained from the prospective study of Huerga et al conducted between September 2009 and 
February 20117. The study included 380 patients of 15 years and older, living within a radius of 10kms 
from the hospital, having at least a cough of two weeks and with two negative smears. Two sputa per 
patient were collected for TLA and LJ cultures. Due to the delay of the TLA culture results, the 
effectiveness criterion was independently assessed in the same patients without taking into account the 
therapeutic decision based on the culture result for conventional algorithm and using culture results for 
the culture-based algorithm (Figures 1 and 2). 
Costs estimation  
The collection of data (Appendix Table A) started on site in 2011 and covers the period from 
September 2009 to February 2011. The cost per patient was estimated for every block of each 
algorithm. The number of patients in each block of the culture-based algorithm is the observed 
numbers and those of the conventional algorithm were derived from the culture-based algorithm 
(Figure 2). Costs, whether direct (resources entirely consumed by the service or joint (shared between 
different services), included variables costs and fixed costs (provisions of depreciation reserve of 
equipment and buildings). Infrastructure costs of the existing laboratory before introduction of culture 
were not considered. Variable costs estimation was based on expenditures, established a posteriori 
from quantities actually used (consumables, fuel, medicine, actual working time) and the price 
obtained in the Kenyan market in 2009, using a conversion rate of 108,7 KES for 1€21. Joint costs 
were calculated based upon allocation keys. 
The staff (clinician, nurse, lab technician) cost was calculated by either multiplying the time spent in 
the activity by the cost of a unit (minute) of work time or from the average number of patients per day. 
The work time of the laboratory technicians in charge of the culture was not easily observable hence 
we adopted the productivity approach22. In 2009, 1195 cultures were carried out at the laboratory, 
equivalent to an average of two tested patients per day (with 2 samples per patient) for each of the 
three laboratory technicians. The unit cost of supervisor work of and maintenance worker was 
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calculated by dividing their wages by the total number of cultures. The unit cost of the person in 
charge of patients’ « tracing » was estimated by dividing his wage by the number of searched people 
from the study period.  For follow-up of TB treatment, patients had weekly nursing consultations (6 
minutes) during first two months and monthly consultation during last four months. For HIV-positive 
patients (74%), there were additional medical consultations (15 minutes) once every two weeks during 
first two months and once per month thereafter.  
The materiel and furniture cost includes the cost of treatment, X-Ray, and laboratory equipment. The 
cost of the first (0.87€) and second (4.4€) antibiotics treatment and TB treatment (22€ for 6 months 
rifampicin based regimen) was based on a lump sum estimated by MSF. The cost of chest X-ray was 
based on a lump sum of 1.84€ per X-ray. The cost of small equipment and furniture for microscopy 
(0.442€ per blade) was based on a previous study in Kenya23. For the culture, the equipment and 
supplies cost included all medical consumables (autoclave pipette, bunsen …), non-medical (gas 
lighter, lamp, sink, strainer …) and reagents expenditures. 
For the running cost, the culture laboratory shared the waste water treatment and waste management 
with the hospital. We allocated 4.06% of this cost to the culture laboratory, using the surface area as 
allocation key. The investment cost included medical and non-medical equipment cost and the 
depreciation of the vehicle used (Table A1). For joint fixed costs, the allocation key was the activity 
for the TB diagnosis linking to the hospital activity. They were allocated into three services, 10.5% for 
microscopy, 59.5% for laboratory equipment or the culture laboratory and 30% for the general 
laboratory. Based on the nomenclature used by the city of Lyon,24 the lifetime for depreciation 
estimation is 10 years for laboratory equipment, 15 years for air-conditioning, seven years for fridges, 
25 years for buildings and three years for motorcycles.  
The total cost was estimated by adding the cost of all different categories listed above according to 
their use in the conventional and culture-based algorithms, respectively (Table 1). 
 
 
 
 
 
 
 
 
	ABC	ABCDE



 
Table 1: Cost calculation process 
 Cost without TLA/LJ 
culture  
Cost with TLA/LJ culture  
A BLOCK  C(a) = Cost of clinical 
examination  + cost of 
chest X-Ray  
C(a) = Cost of clinical examination  
+ cost of chest X-Ray + cost of 
culture 
 C (a’) = C(a) + cost of TB treatment  
B BLOCK  C(b) = C(a) + cost of antibiotic treatment  + cost of second 
clinical examination  + cost of sputum smear microscopy 
 C (b’) = C(b) + cost of TB treatment 
  C (b’’) = C(b) + cost of 
«  tracing »+ cost of TB treatment  
C BLOCK C(c) = C(b) + cost of 2nd antibiotic treatment + cost 3rd clinical 
examination  
 C (c’) = C(c) + cost of TB treatment 
  C(c’’) = c(c) + cost of «  tracing »+ 
cost of TB treatment  
TLA: Thin Layer Agar Culture  
LJ: Löwenstein Jensen Culture 
  TB: tuberculosis  
 
Economic Evaluation  
The efficiency of TLA/LJ culture was estimated by calculating the incremental cost-effectiveness ratio 
(ICER) for the conventional and culture-based diagnostic algorithms (Cost (cult) - Cost / (result (cult) 
- result) 25. The effectiveness outcome was the number of true TB cases (positive culture) starting on 
treatment. There were 33 patients when using the conventional algorithm compared to 60 patients 
when using the culture-based algorithm. Univariate sensitivity analysis was performed on the number 
of TB suspects (1680, as the total number of patients screened at the Homa-Bay laboratory in 2009) 
and on the proportion of true TB cased identified by the culture-based algorithm who were started on 
treatment after been traced. In study condition, the proportion was 100% whereas it was close to 75% 
in programmatic condition7. We used a tracing coverage rate of 75% and 50% for the sensitivity 
analysis. 
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RESULTS  
A total of 380 smear-negative pulmonary TB patients were included in the study7. Following the first 
clinical examination and chest radiography, 66 patients were treated for TB and 314 received an 
antibiotic trial. Among the last ones, 57 were started on TB treatment based on clinical and 
microscopy results, 232 were not considered as TB and withdrawn and 24 patients received a 2nd 
antibiotic trial (Figure 1). In total, 25 patients were secondarily started on treatment after been traced 
due to a positive culture result (Figure 2 and Figure 3). 
 
Figure 3: Diagnostic and treatment pathway for smear-negative TB suspects (N= 380). 
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The costs detail is presented in Tables A1 to A3 in the Appendix. The overall cost of the care of the 
380 smear-negative TB suspects was 15,026€ and 54,931€ with the conventional and culture-based 
algorithms, respectively. In the conventional algorithm, the main costs were human resources’ cost 
(72%), followed by the anti-TB drugs cost (18.2%). The chest radiography represented only 4.6% of 
the total cost. With the culture-based algorithm, the human resources’ cost represented only 39.4% of 
the overall cost, while the cost of materials and supplies participated for almost half of the cost 
(42.8%). The average cost per screened TB suspect was 39.5€ and 144.5€ for the conventional and 
culture-based algorithms, respectively. The cost per true TB case started on treatment was 455.3€ 
when using the conventional algorithm compared to 915.5€ when using the culture-based algorithm 
(Table 2). As shown by the ICER, the culture allowed starting TB treatment in 27 additional true TB 
cases for a total additional cost of 39,905€, equivalent of 1,478€ per new true TB case started on 
treatment (Table 3). 
 
Table 2: Cost-effectiveness of screening negative TB cases with and without TLA / JL culture  
Diagnostic algorithms  Cost Effectiveness 
(Screened and 
treated cases) 
Cost-
effectiveness 
ratio (euros) 
P1Algorithm without TLA/LJ culture, 380 
patients 
 
15026 33 455,2 
P2Algorithm with TLA/LJ culture, 100% of 
tracing coverage, 380 patients 
 
54931 60 915,5 
P2’Algorithm with TLA/LJ culture, 75% of 
tracing coverage, 380 patients 
 
53710 52 1032,9  
P2’’Algorithme with TLA/LJ culture, 50% 
of coverage tracing, 380 patients 
 
52498 45 1166,6  
P3Algorithme without TLA/LJ culture, 
1680 patients 
 
66380 146 454,7 
P4Algorithm with TLA/LJ culture, 100% of 
coverage tracing, 1680 patients 
 
200802 265 757,7 
P4’Algorithm with TLA/LJ culture, 75% of 
coverage tracing, 1680 patients 
 
195823 230 851,4  
P4’’Algorithm with TLA/LJ culture, 50% 
of tracing coverage, 1680 patients 
183910 199 924,2  
 
Using 75% and 50% of proportion of culture positive patients effectively started on treatment after 
tracing, the average cost per screened patient was 141.3€ and 138.1€, respectively euros. The ICER 
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indicates that the cost per new true TB case started on TB treatment was 2036€ for a tracing coverage 
of 75% and 3122.7€ for a tracing coverage of 50% (Table 3).  
When the number of patients is increased to 1680, the average cost per screened patient using the 
conventional algorithm was 39.5€ (Table A2). Using the culture-based algorithm with a tracing 
coverage of 100%, 75% and 50%, the average cost per screened patient was 119.5€, 116.5€ and 
109.4€, respectively (Tables 2 and A3). The ICER per new true TB case started on treatment was 
1129.6€, 1541€ and 2217.5€ with the respective tracing coverage of 100%, 75% and 50% (Table 3). 
 
Table 3: Incremental Cost Effectiveness Ratio 
 
Program 
Costs 
(euros) 
Screened 
and treated 
cases  (E) 
C E ICER 
(C) 
P1 15026 33 15026 33 455,3 
P2 54931 60 39905 27 1478,0 
P2’ 53710 52 38684 19 2036,0 
P2" 52498 45 37472 12 3122,7 
            
P3 66 380 146 66 380 146 454,7 
P4 200802 265 134 422 119 1129,6 
P4’ 195823 230 129 443 84 1541,0 
P4" 183910 199 117 530 53 2217,5 
 
DISCUSSION  
The cost analysis was considered from the district hospital perspective and does not include the cost 
for the patient. The culture-based algorithm was more expensive than the conventional algorithm. 
Indeed, it requires expensive equipment and many supplies whereas the conventional algorithm 
without culture depends mainly on human resources. The use of thresholds in decision-making has 
met some criticism, such as, among others, the risk of uncontrolled growth in health-care expenditure. 
However, thresholds represent the societal willingness-to-pay for health-care, and for that, this 
decision rule is considered more appropriate for societal decision-makers26. Moreover, budget impact 
analysis can complement cost-effectiveness analysis. The WHO27, considers cost-effective a strategy, 
which the cost-effectiveness ratio is less than three times the GDP per inhabitant of the country where 
the strategy is implemented.  
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Despite a higher global cost, the culture-based algorithm was cost-effective. The cost per true TB case 
started on treatment (915.5€) was less than three times the GDP per capita of Kenya (1668€ in 2009)28. 
The sensitivity analysis showed that the cost-effectiveness of the culture algorithm improved (757.7€) 
if we multiply, given the available resources of the studied laboratory, by four the number of screened 
patients. When the tracing coverage rate drops to 50%, the culture-based algorithm remained cost-
effective (924.2€, by true TB case started on treatment) regardless of the total number of screened 
patients. The additional cost per true TB case started on treatment with a tracing rate of 100% is not 
excessive (1478€) compared to the average cost (915€). It remains true when the tracing rate decreases 
to 75%.  
The total cost for the diagnosis of presumed smear-negative TB increased from 15,026€ (without 
culture) to 54,931€ (with culture), which would require to multiply by 3.5 or 4 the amount of financial 
resources. The adoption of the 2007 WHO revised algorithm at the national scale would imply the 
creation of several laboratories with high-level of infrastructure and staff with expertise12. It is 
therefore important to first ensure that the introduction of the culture is consistent with financial 
sustainability/affordability at the medium and long term, without risk to the financial situation of 
Kenya. 
Cost-effectiveness studies about algorithm with culture in limited resources countries are relatively 
scarce15  and we do not know any of the TLA culture. In addition, the comparison is difficult, the 
effectiveness outcome being not always the same29. Mueller et al. in a study on Zambia found a cost 
per detected case of 134€ with the MGIT culture and 231€ with the LJ culture30. When they focused 
on the smear negative TB suspects, the cost was 413€ with MGIT. 
In this study, the culture contributed to put under treatment 27 patients who had escaped the clinical 
and radiological diagnosis who represented 42% of all TB confirmed patients. However, it requires an 
effective tracing of patients with a positive culture. Also, the long delays of culture results limit the 
impact of culture on the therapeutic decision. Therefore, the use of culture does not allow to reduce the 
potentially proportion of patients wrongly started on treatment based on clinical and radiological 
findings. A test with a similar sensitivity to the culture, but much faster would have more impact on 
the treatment decision, and would be probably more cost effective. Among the currently available 
tests, the XpertMTB/RIF assay is the one that comes closest to this ideal test with a sensitivity of 70% 
in smear-negative TB suspects compared with culture and results available in 2h31. This test has also 
the advantage of requiring infrastructure and expertises that are close the ones required by 
microscopy32.  
 
  
	ABC	ABCDE

(

CONCLUSION  
This study is one of the few studies documenting the cost-effectiveness of a diagnostic algorithm for 
pulmonary TB using the rapid culture of MTB in a district hospital of an area with high HIV 
prevalence and limited resources. Although cost-effective according to the WHO criteria, the use of 
MTB culture remains an expensive examination with a too long delay for results increasing the risk of 
over-diagnose patients. 
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Appendix 
 
Table A: Identification and cost valorisation 
Costs type Identification Measure method Valorisation Data source  
A. Variable Costs     
Staff  Clinical staff 
Culture staff 
Tracing staff  
Sputum smear microscopy staff  
Training staff 
 
 
    Actual working 
time per patient 
 
Time spent in 
training (<1an) 
 
 
 
     Net wage 
 
 
  MSF RH 
Materials and 
furniture 
 
 
 
 
 
 
 
Functioning and 
maintenance of 
building 
 
 
 
 
 
 
Functioning and 
maintenance of 
vehicles 
 
B. Fixed costs 
Medical equipment 
 
 
 
Non-medical 
equipment  
 
Infrastructures  
 
Vehicles  
Drugs 
Reagent, radio film 
Consumables 
Laboratory supplies (spatula, 
tube…) 
Small medical equipment 
Small non-medical equipment 
 
Electricity  
Cleaning 
Plumbing  
Painting 
Building renovation  
Medical maintenance  
Non-medical maintenance 
Water treatment  
 
Fuel 
 
 
 
 
Autoclave, incubator, precision 
scale, water distiller, biosafety 
cabinet, X-Ray… 
Air conditioning, fridges, 
computer… 
 
Building electrical and plumbing 
system 
Vehicle purchased 
Daily quantity 
consumed, lump 
 
 
 
 
 
 
 
Quantity consumed   
 
 
Based on the area 
 
 
 
 
Quantity consumed  
 
 
 
Depreciation 
calculation 
 
Market prices  
 
 
 
 
 
 
Market prices  
 
 
 
 
 
 
 
 
Market prices  
 
 
 
Market prices  
& lifetime  
Bills recorded in 
accounting records  
 
 
 
 
 
Bills recorded in 
accounting records  
 
 
 
 
 
 
 
Bills recorded in 
accounting records  
 
 
Bills recorded in 
accounting records  
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TableA2: Cost components of screening (tracing = 100%), with and without TLA / LJ culture, in € and (%), 
2009 
 Algorithm 
  380 patients 1680 patients 
Cost components Without TLA/LJ 
culture 
With TLA/LJ 
culture 
Without  
TLA/LJ culture 
 
With TLA/LJ 
culture 
 
 
Staff 
 
 
10833,5 
(72,1) 
 
21617,3 
(39,4) 
 
47850 
(72,1) 
 
66266,3 
(33,0) 
Staff training  0 
(0) 
117,1 
(0,2) 
0 
(0) 
184,1 
(0,1) 
Chest X-Ray  695,4 
(4,6) 
695,4 
(1,3) 
3074,5 
(4,63) 
3074,5 
(1,5) 
Antibiotic treatment  372,5 
(2,5) 
372,5 
(0,7) 
1643,9 
(2,48) 
1663,8 
(0,8) 
Functioning  40,9 
(0,3) 
1943,2 
(3,5) 
181,2 
(0,27) 
3199,1 
(1,6) 
Material and furniture  301,5 
(2,0) 
23507,1 
(42,8) 
1332,6 
(2,01) 
104105,9 
(51,8) 
Medical equipment  20,4 
(0,1) 
1863,7 
(3,4) 
90,6 
(0,14) 
2997,4 
(1,5) 
Non-medical 
equipment   
34,2 
(0,2) 
269 
(0,5) 
151,2 
(0,23) 
2211,5 
(1,1) 
TB treatment  2728 
(18,2) 
3300 
(6,0) 
12056 
(18,16) 
14652 
(7,3) 
Infrastructure  0 
(0) 
1082 
(2,0) 
0 
(0) 
1707,3 
(0,9) 
Motorcycle 
depreciation   
0 
(0) 
104 
(0,2) 
0 
(0) 
472 
(0,2) 
Motorcycle 
maintenance  
0 
(0) 
60 
(0,1) 
0 
(0) 
271,3 
(0,1) 
 
 
Total  
 
Cost per patient 
 
 
15026 
 
39,5 
 
54931 
 
144,5 
 
 
66380 
 
39,5 
 
200802 
 
115,5 
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Table A3: Cost components of screening (tracing = 75% an 50%) with and without TLA / LJ culture, in € and 
(%), 2009 
 Algorithm 
 75% tracing 50% tracing 
Cost components With  
TLA/LJ culture  
380 patients  
With  
TLA/LJ culture  
1680 patients,   
With TLA/LJ 
culture 
380 patients  
With  
TLA/LJ culture  
1680 patients  
Staff 20937,8 
(39,0) 
64113,2 
(32,7) 
20493 
(39,0) 
55136,9 
(30,0) 
Staff training 115,5 
(0,2) 
181 
(0,1) 
113,4 
(0,2) 
177,8 
(0,1) 
Chest X-Ray 686,2 
(1,3) 
3021,2  
(1,5) 
673,4 
(1,3) 
2967,8 
(1,6) 
Antibiotic treatment 372,6 
(0,7) 
1633,5  
(0,8) 
357,8 
(0,7) 
1592,2 
(0,9) 
Functioning  1916,8  
(3,6) 
3142,2  
(1,6) 
1880  
(3,6) 
3083,4 
(1,7) 
Material and furniture 23191,7  
(43,2) 
102340,1  
(52,3) 
22750,4  
(43,3) 
100511,3 
(54,7) 
Medical equipment 1838,6  
(3,4) 
2945,6 
 (1,5) 
1803,7  
(3,4) 
2891,9 
(1,6) 
Non-medical 
equipment   
264,6  
(0,5) 
2171,7 
 (1,1) 
259  
(0,5) 
2130,5 
(1,2) 
TB treatment 3190  
(5,9) 
14036  
(7,2) 
3036  
(5,8) 
13398 
(7,3) 
Infrastructure  1066,7  
(2,0) 
1678,7 
(0,9) 
1046,7  
(2,0) 
1649,1 
(0,9) 
Motorcycle 
depreciation 
82,7 
(0,2) 
355,9  
(0,2) 
53,8 
(0,1) 
236 
(0,1) 
Motorcycle 
maintenance 
47,5 
(0,1) 
204,6  
(0,1) 
30,9  
(0,1) 
 
135,7 
(0,1) 
Total  
 
 
Cost per patient  
53710,8 
(100) 
 
141,3 
195823,4 
(100) 
 
116,5 
52498,7 
(100) 
 
138,1 
183910,5 
(100) 
 
109,4 
 
 
 
 
 
 
 
 
 
 
 
